Update Psychopharmacotherapy.

Area of Science:

• Psychiatry and Pharmacology
• Neuroscience and Mental Health

Background:

• Significant unmet needs exist in psychotropic drug efficacy, tolerability, and onset of action.
• Despite the high burden of mental disorders, few novel psychotropic medications have recently been approved in Germany.
• Economic factors and assessments of additional benefit significantly influence market availability.

Purpose of the Study:

• To review recent developments in psychotropic drug introductions and withdrawals in Germany and the USA.
• To highlight advancements in the treatment of schizophrenia, ADHD, depression, alcohol consumption, and obesity.
• To discuss challenges and the urgent need for continued psychotropic drug development.

Main Methods:

• Review of recently introduced and withdrawn psychotropic medications in key markets (Germany, USA).
• Analysis of specific drug classes, including antidepressants, antipsychotics, and agents for substance use and metabolic disorders.
• Consideration of novel formulations and administration routes (e.g., inhalative, long-acting depots).

Main Results:

• Lurasidone and vortioxetine withdrawn in Germany; nalmefene, guanfacine, milnacipran, and liraglutide introduced.
• New atypical antipsychotics (cariprazine, brexpiprazole) released in the USA; long-acting antipsychotics approved in Europe.
• Loxapine available for agitation; quetiapine recommended for treatment-resistant depression; ketamine and botulinum toxin under investigation.

Conclusions:

• The psychotropic drug development pipeline faces significant economic and regulatory hurdles, alongside negative public perception.
• Recent innovations include long-acting antipsychotics, novel antidepressants, and treatments for specific conditions like ADHD and alcohol dependence.
• Urgent constructive efforts are required to prevent stagnation in the development of essential psychotropic medications.